Novartis to present new haematology findings at ASH 2015

Novartis has announced that it will be attending the American Society of Hematology (ASH) annual meeting in Florida from December 5th to 8th.

The company will be presenting its latest research data and portfolio information, including findings on leukaemias, lymphomas and myelomas, as well as supportive care and personalised cell therapies.

Pivotal overall survival data for the investigational compound PKC412 in adults with newly diagnosed FLT3-mutated acute myeloid leukaemia will be shared, as well as results showing the efficacy of biosimilar pegfilgrastim in chemotherapy-induced neutropenia.

Presentations will also highlight new CTL019 data in relapsed/refractory acute lymphoblastic leukaemia and non-Hodgkin lymphoma.

Bruno Strigini, president of Novartis Oncology, said: "We will be presenting encouraging overall survival data for both investigational and approved products, underscoring our commitment to improve and extend people's lives."

A key focus in hematology for Novartis is developing therapies for rare and difficult-to-treat patient populations, with acute myeloid leukaemia highlighted as a particular priority.